Why Investors Are Excited about Advaxis
Advaxis (ADXS), in collaboration with Merck (MRK), is conducting a Phase 1 Part 2 trial to evaluate the safety and efficacy of ADXS-PSA.
FDA Lifts Hold on Clinical Trial: Major Boost for Advaxis
In a major development, Advaxis announced on July 13 that the FDA has lifted its hold on the IND (Investigational New Drug) application.
Why Advaxis Stock Is Soaring Today
Today, Advaxis (ADXS) is trading at $1.43, which represents a rise of ~16.80% from yesterday’s close of $1.22.
XBI Recovers from Its Slump
The SPDR S&P Biotech ETF (XBI) and the iShares Nasdaq Biotechnology ETF (IBB) were the top biotechnology ETFs last week, returning 5.3%, and 3.7%.
Advaxis Led the Bottom Ten Biotechnology Stocks by Market Cap
Advaxis (ADXS), which has a weight of 0.61% in the SPDR S&P Biotechnology (XBI) ETF, rose 24.54% for the week ended September 11, 2015.